Cargando…

Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis

BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) has substantially reduced disease burden due to Streptococcus pneumoniae, a leading cause of childhood morbidity and mortality globally. However, PCVs are among the most expensive vaccines, hindering their introduction in some settin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Cynthia, Cervero Liceras, Francisco, Flasche, Stefan, Sidharta, Sucitro, Yoong, Joanne, Sundaram, Neisha, Jit, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293964/ https://www.ncbi.nlm.nih.gov/pubmed/30554762 http://dx.doi.org/10.1016/S2214-109X(18)30422-4

Ejemplares similares

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

The broader economic impact of vaccination: reviewing and appraising the strength of evidence
por: Jit, Mark, et al.
Publicado: (2015)

High use of private providers for first healthcare seeking by drug-resistant tuberculosis patients: a cross-sectional study in Yangon, Myanmar
por: Sidharta, Sucitro Dwijayana, et al.
Publicado: (2018)

The global impact and cost-effectiveness of a melioidosis vaccine
por: Luangasanatip, Nantasit, et al.
Publicado: (2019)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Economic interventions to improve population health: a scoping study of systematic reviews
por: Khan, Mishal S., et al.
Publicado: (2016)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study
por: Flasche, Stefan, et al.
Publicado: (2011)

Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam
por: Le Polain De Waroux, Olivier, et al.
Publicado: (2018)

Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru
por: Gomez, Jorge Alberto, et al.
Publicado: (2013)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

The Serotype Distribution among Healthy Carriers before Vaccination Is Essential for Predicting the Impact of Pneumococcal Conjugate Vaccine on Invasive Disease
por: Flasche, Stefan, et al.
Publicado: (2015)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
por: Li, Yan, et al.
Publicado: (2021)

Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications
por: Pecenka, Clint, et al.
Publicado: (2021)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales
por: Choi, Yoon Hong, et al.
Publicado: (2012)

Pneumococcal vaccine schedules (PVS) study: a cluster-randomised, non-inferiority trial of an alternative versus standard schedule for pneumococcal conjugate vaccination—statistical analysis plan
por: Mackenzie, Grant A., et al.
Publicado: (2022)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya
por: Ojal, John, et al.
Publicado: (2019)

Effectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine
por: Antony, Katja, et al.
Publicado: (2005)

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model
por: Bakır, Mustafa, et al.
Publicado: (2012)

Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
por: Ordóñez, Jaime E, et al.
Publicado: (2014)

Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Systematic Review of the Indirect Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Pneumococcal Disease and Colonization
por: Loo, Jennifer D., et al.
Publicado: (2014)

Effect of Age and Vaccination With a Pneumococcal Conjugate Vaccine on the Density of Pneumococcal Nasopharyngeal Carriage
por: Roca, A., et al.
Publicado: (2012)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean
por: Whitney, Cynthia G, et al.
Publicado: (2021)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
por: van Hoek, Albert Jan, et al.
Publicado: (2016)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
por: Lee, Hyunju, et al.
Publicado: (2014)

Methodological criticisms in the evaluation of Pneumococcal Conjugate Vaccine effectiveness
por: TRUCCHI, C., et al.
Publicado: (2015)

Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools
por: Chaiyakunapruk, Nathorn, et al.
Publicado: (2011)

Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia
por: Ordóñez, Jaime E, et al.
Publicado: (2015)

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
por: Wilson, Michele, et al.
Publicado: (2023)

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Immunogenicity
por: Deloria Knoll, Maria, et al.
Publicado: (2014)

The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries
por: Flasche, Stefan, et al.
Publicado: (2015)

Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations
por: Naucler, Pontus, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mgj5hpf6p24jtsaepgb5a5v8sh